Bioprosthetic or Native Aortic Scallop Intentional Laceration to Prevent Iatrogenic Coronary Artery Obstruction (BASILICA) Prospective Investigation (BASILICA)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03381989|
Recruitment Status : Active, not recruiting
First Posted : December 22, 2017
Results First Posted : March 24, 2020
Last Update Posted : March 24, 2020
TAVR is a common therapy for people with heart problems. It stands for transcatheter aortic valve replacement, TAVR can be a better option than surgery. But it isn t safe for everyone. It may block the arteries that supply blood to the heart muscle by pushing heart valve tissue outward. Researchers want to study a method that may make TAVR safer. It is known as Bioprosthetic or native Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction (BASILICA).
To study the feasibility and safety of BASILICA in people at high risk of coronary artery obstruction that complicates TAVR.
People at least 21 years old whose heart doctors do not think they can have TAVR safely
Participants will be screened by a team of heart specialists. They will have heart and blood tests. They will answer questions.
Participants will have TAVR using BASILICA.
They will get general anesthesia or they will be sedated.
While using x-rays and echocardiography, doctors will cross and split the aortic valve leaflet using an electrified wire.
A standard TAVR valve will be implanted.
After the procedure, participants will have blood tests and physical exams. They will answer questions. They will have heart tests.
Participants will have a scan within 1 month and after 12 months. They will have heart tests during follow-up visits in the first year.
Sponsoring Institute: National Heart, Lung and Blood Institute
|Condition or disease||Intervention/treatment||Phase|
|Native and Valve in Valve Aortic Valve Failure||Device: ASHI_INTECC Astato XS 20 0.014 guidewire||Not Applicable|
Transcatheter aortic valve replacement (TAVR) is an option to treat aortic valve stenosis or failure of a surgically implanted tissue valve. Sometimes TAVR displaces the diseased aortic valve leaflets outwards, causing life-threatening obstruction of the coronary arteries that supply blood to the heart. This is more common in surgically implanted tissue valves that are designed to achieve the largest aortic valve orifice area. Despite attempts to protect the coronary arteries from obstruction in these patients using coronary stents, the mortality of TAVR-associated coronary artery obstruction remains prohibitively high.
The investigators have developed and tested a technique to tear the existing aortic valve leaflet and enable TAVR in such patients. The procedure is called Bioprosthetic or native Aortic Scallop Intentional Laceration to prevent Iatrogenic Coronary Artery obstruction (BASILICA).
The purpose of this study is to perform BASILICA in patients who have no good options to prevent coronary artery obstruction during TAVR.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||31 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Bioprosthetic or Native Aortic Scallop Intentional Laceration to Prevent Latrogenic Coronary Artery Obstruction (BASILICA)|
|Actual Study Start Date :||February 14, 2018|
|Actual Primary Completion Date :||September 30, 2018|
|Estimated Study Completion Date :||November 13, 2020|
Experimental: Single arm: open-label treatment
The BASILICA procedure has three steps: (1) leaflet traversal with a guidewire, followed by (2) leaflet laceration, immediately followed by (3) TAVR.
Device: ASHI_INTECC Astato XS 20 0.014 guidewire
A coaxial traversal guiding catheter system (typically tandem catheters) directs electrosurgery devices (typically a rigid 0.014 guidewire inside a polymer jacket wire convertor) against the base of the coronary cusp targeted for laceration, using fluoroscopic and/or echocardiographic guidance. Traversal is accomplished by transcatheter electrosurgery by connecting the back end of the 0.014 guidewire to an electrosurgery pencil during short bursts of pure, cutting radiofrequency energy at ap-proximately 30W. The guidewire is repositioned as needed until it crosses the aortic leaflet and is snare-retrieved and externalized. Laceration is performed by positioning the laceration surface along the intended leaflet base, and applying tension on both free ends of the guidewire while simultaneously apply electrosurgery energy (typically 70W) in short bursts, until the laceration is complete and the guidewire is free.
- Procedure Success, Measured at Exit From the Catheterization Laboratory [ Time Frame: 1 day ]Successful BASILICA traversal and laceration; immediate survival; successful first TAVR device implantation; absence of coronary artery obstruction; and freedom from emergency cardiac surgery or reintervention related to the BASILICA or TAVR procedure.
- Safety Endpoint is Freedom From Major Adverse Clinical Events (MACE) [ Time Frame: 30 days ]Freedom from major adverse clinical events (MACE) according to Valve Academic Research Consortium (VARC-2) at 30days.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03381989
|United States, District of Columbia|
|Medstar Washington Hospital Center|
|Washington, District of Columbia, United States, 20010|
|United States, Georgia|
|Emory University Hospital|
|Atlanta, Georgia, United States, 30322|
|United States, Michigan|
|Henry Ford Hospital|
|Detroit, Michigan, United States, 48202|
|United States, Washington|
|University of Washington|
|Seattle, Washington, United States, 98195|
|Principal Investigator:||Robert J Lederman, M.D.||National Heart, Lung, and Blood Institute (NHLBI)|